Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.

ABSTRACT:

Importance

Biomarkers do not determine conversion to Alzheimer disease (AD) perfectly, and criteria do not specify how to take patient characteristics into account. Consequently, biomarker use may be challenging for clinicians, especially in patients with mild cognitive impairment (MCI).

Objective

To construct biomarker-based prognostic models that enable determination of future AD dementia in patients with MCI.

Design, setting, and participants

This study is part of the Alzheimer's Biomarkers in Daily Practice (ABIDE) project. A total of 525 patients with MCI from the Amsterdam Dementia Cohort (longitudinal cohort, tertiary referral center) were studied. All patients had their baseline visit to a memory clinic from September 1, 1997, through August 31, 2014. Prognost

SUBMITTER: van Maurik IS 

PROVIDER: S-EPMC5822193 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature